



A/Prof Charles Chuah is a Senior Consultant at the Department of Haematology, Singapore General Hospital (SGH) and National Cancer Centre Singapore and Associate Professor at the Cancer and Stem Cell Biology Program, Duke-NUS Medical School. He currently holds leadership appointments as Director, Office of Translational Medicine Oversight (TMO), SGH; Vice Chair, Research, SingHealth Duke-NUS Medicine Academic Clinical Program (ACP); Director, Research, SingHealth Duke-NUS Blood Cancer Centre; and Director, Myeloproliferative Disorders/Chronic Myeloid Leukemia Program, Department of Haematology, SGH.

A/Prof Chuah's research spans the translational research spectrum from laboratory discoveries to clinical trials. His research efforts have centred on chronic myeloid leukaemia (CML) with a particular emphasis on targeted therapy and mechanisms of treatment resistance. His track record in research is excellent and of international standing. In the past fifteen years, he has secured more than S\$5 million dollars of funding from national and institutional grants, including two prestigious NMRC Clinician Scientist Awards. He was a member of the NMRC Scientific Review Panel (2007-2019). A/Prof Chuah is currently the Theme and Core Lead Principal Investigator (PI) of an NMRC Collaborative Centre Grant. This collaborative grant brings together clinicians, clinician scientists and scientists from four public healthcare institutions to establish a national collaborative platform of international renown to advance translational research and clinical care in blood cancer.

A/Prof Chuah has published extensively in his field of research. He has more than 70 peer-reviewed publications in major journals in medicine, haematology and oncology. A/Prof Chuah is also Principal Investigator in 23 multi-centre clinical trials. Participation in these trials have enhanced the reputation of the institution and nation and more importantly, gave patients access to novel therapies which would have otherwise not been available. Of note were two US Food and Drug Administration (FDA) drug registration trials. Results from these two trials led to FDA approval and were published in the prestigious New England Journal of Medicine. A/Prof Chuah was a co-author in both publications in recognition of his significant contribution to the trials.

A/Prof Chuah has made major contributions to the area of clinical practice. He was a panel member of the National Comprehensive Cancer Network (NCCN) Asia for CML and Co-chair for the NCCN (Asia) Consensus Statement Panel for CML in 2008. A/Prof Chuah is widely regarded as an international key opinion leader in his field and has been invited regularly to speak at international, regional and national meetings, serve on abstract review panels at international scientific meetings and participate in scientific advisory boards.